Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel.
Share Price & News
How has Cellect Biotechnology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APOP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: APOP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: APOP exceeded the US Life Sciences industry which returned 45.7% over the past year.
Return vs Market: APOP exceeded the US Market which returned 30.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cellect Biotechnology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Cellect Biotechnology Fundamentals Summary
|APOP fundamental statistics|
Is APOP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|APOP income statement (TTM)|
|Cost of Revenue||₪0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-4.20|
|Net Profit Margin||0.00%|
How did APOP perform over the long term?See historical performance and comparison
Is Cellect Biotechnology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate APOP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate APOP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: APOP is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: APOP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APOP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APOP is overvalued based on its PB Ratio (12.9x) compared to the US Life Sciences industry average (5.7x).
How is Cellect Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cellect Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cellect Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APOP is currently unprofitable.
Growing Profit Margin: APOP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APOP is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare APOP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APOP is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (55.2%).
Return on Equity
High ROE: APOP has a negative Return on Equity (-289.46%), as it is currently unprofitable.
How is Cellect Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: APOP's short term assets (₪9.9M) exceed its short term liabilities (₪3.3M).
Long Term Liabilities: APOP's short term assets (₪9.9M) exceed its long term liabilities (₪2.8M).
Debt to Equity History and Analysis
Debt Level: APOP is debt free.
Reducing Debt: APOP had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APOP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: APOP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.4% each year
What is Cellect Biotechnology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APOP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APOP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APOP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APOP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APOP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shai Yarkoni (63 yo)
Dr. Shai Yarkoni, M.D., Ph D., co-founded Cellect Biotherapeutics subsidiary of Cellect Biotechnology Ltd. in 2011.He has been the Chief Executive Officer of Cellect Biotechnology Ltd. since July 04, 2013...
CEO Compensation Analysis
Compensation vs Market: Shai's total compensation ($USD546.21K) is about average for companies of similar size in the US market ($USD545.00K).
Compensation vs Earnings: Shai's compensation has been consistent with company performance over the past year.
Experienced Management: APOP's management team is seasoned and experienced (5.7 years average tenure).
Experienced Board: APOP's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cellect Biotechnology Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Cellect Biotechnology Ltd.
- Ticker: APOP
- Exchange: NasdaqCM
- Founded: 1986
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$24.197m
- Shares outstanding: 3.92m
- Website: https://www.cellect.co
Number of Employees
- Cellect Biotechnology Ltd.
- 23 Hata’as Street
- Kfar Saba
Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 04:51|
|End of Day Share Price||2021/09/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.